Paper Details

  1. Home
  2. Paper Details

Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.

Author: AlphsLarry, CazorlaPilar, PhiriPhillip, PotkinSteven G, SzegediArmin, ZhaoJun

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This pooled analysis of two 26-week core studies with 26-week extensions compared asenapine and olanzapine as monotherapies in reducing persistent negative symptoms in schizophrenia. While neither study met the primary endpoint of superiority of asenapine over olanzapine, asenapine was statistically superior to olanzapine in one extension study. This analysis provides insights into the treatment effects of both drugs.
Paper Details　
Original Abstract of the Article :
A Phase 2 efficacy study suggested that asenapine (ASE) was superior to risperidone in decreasing negative symptoms in schizophrenia at 6 weeks, prompting design of two negative symptom studies. Two 26-week core studies with 26-week extensions compared asenapine (ASE: 5-10mg twice-daily] and olanzap...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.schres.2013.08.024

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Treatment of Persistent Negative Symptoms in Schizophrenia

Imagine a desert where the sand is constantly shifting, making it difficult to find a stable footing. This is an analogy for the experience of individuals with schizophrenia, who often face persistent negative symptoms that can make daily life challenging. This study focuses on two medications, asenapine and olanzapine, and their effectiveness in treating these persistent negative symptoms. Researchers investigated whether asenapine offered a potential advantage over olanzapine in improving these debilitating symptoms.

A Glimpse into the Desert of Schizophrenia Treatment

The study found that neither asenapine nor olanzapine consistently outperformed the other in treating persistent negative symptoms. However, asenapine did show some promise in a subsequent extension study. These findings suggest that there may be a need for further research to explore the potential benefits of asenapine in addressing these specific symptoms.

Navigating the Complexities of Schizophrenia

This study highlights the ongoing challenges of finding effective treatments for persistent negative symptoms in schizophrenia. It underscores the need for personalized approaches that consider individual patient needs and explore the potential of different medications. The research encourages continued exploration of treatment options to improve the lives of those living with this complex mental health condition.

Dr.Camel's Conclusion

This study is a reminder that the desert of schizophrenia treatment is a complex landscape with many challenges. While asenapine shows some potential in addressing persistent negative symptoms, further research is needed to fully understand its efficacy and optimize its use. The quest for effective treatments for schizophrenia is an ongoing journey, requiring continued exploration and innovation to improve the lives of those affected by this condition.

Date :
  1. Date Completed 2014-06-20
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

24075603

DOI: Digital Object Identifier

10.1016/j.schres.2013.08.024

Related Literature

Article Analysis
・Effects of asenapine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.